ClinicalTrials.gg
RecruitingNCT05951179ADVANCED-2Updated Aug 24, 2026

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

A Phase 2 interventional study of TARA-002 in Non-muscle Invasive Bladder Cancer, sponsored by Protara Therapeutics. Recruiting at 78 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-24.

Sponsored by Protara Therapeutics · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
131
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States — 39 open to participants now, 60 under way, 15 of them phase 3. Non-Muscle Invasive Bladder Neoplasms · United States.

Planned enrollment
31st of 93
131 · median 55
Started
2023
with 13 others
Phase 2
20 of 114
8 open now
Primary completion
2031-10
later than 54 of 59 live
Registered
73rd of 114
by date
Lead sponsor
4 of 114
Protara Therapeutics

Among the 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States, this one is the 31st largest by planned enrollment of the 93 interventional ones that give a count, is one of 14 that started in 2023, is one of 20 in phase 2, reaches primary completion later than 54 of the 59 other live ones, and was the 73rd registered.

Non-Muscle Invasive Bladder Neoplasms

294 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 126 are open to participants now.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Open to participants now

39 of the 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 93 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 78 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States, or all of them as a file.
02

Study summary

TARA-002-101-Ph2 is an open-label study to investigate the safety and efficacy of intravesical instillation of TARA-002 in adults 18 years of age or older with high-grade CIS NMIBC (± Ta/T1).

The purpose of this Phase 2 study (TARA-002-101-Ph2) is to further assess the safety and efficacy of TARA-002 at the RP2D which has been established in the Phase 1a dose finding study (TARA-002-101-Ph1a).

This Phase 2 study includes participants with CIS NMIBC (± Ta/T1) with active disease, defined as disease present at last tumor evaluation (within 3 months) prior to signing the ICF.

Participants will be enrolled into one of 2 cohorts:

Cohort A:

  • Participants with CIS (± Ta/T1) who are BCG naive, or
  • Participants with CIS (± Ta/T1) who are BCG exposed and have not received intravesical BCG for at least 24 months prior to the most recent CIS diagnosis

Cohort B:

  • Participants who are BCG unresponsive
03

Conditions studied

  • Non-muscle Invasive Bladder Cancer

Keywords

  • Non-muscle invasive bladder Cancer
  • bladder cancer
  • high grade Ta
  • high grade NMIBC
  • carcinoma in situ
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants 18 years of age or older at the time of signing
  • Participants who have voluntarily given written informed consent after the nature of the study has been explained according to applicable requirements prior to study entry
  • Central histologic confirmation of high-grade non-muscle invasive CIS (± Ta/T1) with active disease
  • Participants who are BCG naive, or participants who are BCG exposed and have not received intravesical BCG for at least 24 months prior to the most recent CIS diagnosis (Cohort A). Participants with CIS (± Ta/T1) who are BCG unresponsive.

Exclusion criteria

Exclusion Criteria:

  • Penicillin allergy (participants with a questionable history of allergy to penicillin will undergo penicillin blood allergy testing via central laboratory
  • Central confirmed variant histology
  • Concomitant prostatic or upper tract urothelial involvement per Investigator's assessment
  • Nodal and disease are excluded if they existed at any time (whether present or in the past)
  • Any history of ≥ T2 bladder cancer that existed at any point in time in the participant's history

For more information on eligibility criteria, please contact the Sponsor

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
131 participants (estimated)

Study arms

  • Experimental
    TARA-002

    TARA-002 is a lyophilized biological preparation for instillation containing cells of Streptococcus pyogenes (Group A, type 3) Su strain.

    Biological: TARA-002

Interventions

  • BiologicalTARA-002

    Drug pages: Picibanil · Lyophilized Inactivated Group A Streptococcus TARA-002

    All participants will receive 6 weekly instillations of TARA-002 at the established RP2D (First Treatment Period). Participants who are eligible for reinduction after the First Treatment Period will receive 6 additional weekly doses of TARA-002 instillation as part of the Second Treatment Period. Participants confirmed to have a complete response after the First Treatment Period will receive 3 additional weekly doses of TARA-002 instillation as maintenance during the Second Treatment Period. All eligible participants will receive 3 weekly doses of TARA-002 instillation as part of the Third Treatment Period (maintenance) at Months 6, 9, 12, 15, 18 and 24. Following the Third Treatment Period, all participants will continue to the Follow up Period from Month 27 until Month 60.

06

What researchers measure

Primary outcomes

  1. Cohort A and B: Incidence of high-grade Complete Response at any time according to central pathology after treatment with TARA-002

    Time frame: Month 3 to Month 60

Secondary outcomes

  1. Cohort A: Incidence of high-grade Complete Response at any time by subgroup (BCG naive and BCG exposed > 24 months) according to central pathology after treatment with TARA-002

    Time frame: Month 3 to Month 60

  2. Cohort A and B: Duration of high-grade Complete Response rate at Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 36, 42, 48, 54, and 60 after treatment with TARA-002

    Time frame: Month 3 to Month 60

  3. Cohort A and B: High-grade Complete Response rate at Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 36, 42, 48, 54, and 60 after treatment with TARA-002

    Time frame: Month 3 to Month 60

  4. Cohort A and B: Duration of Complete Response (all recurrent bladder cancer, including low grade Ta) after treatment with TARA-002

    Time frame: Month 3 to Month 60

  5. Cohort A and B: Complete Response rate (all recurrent bladder cancer, including low grade Ta) at Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 36, 42, 48, 54, and 60 after treatment with TARA-002

    Time frame: Month 3 to Month 60

  6. Cohort A and B: Progression free survival after treatment with TARA-002

    Time frame: 60 months

  7. Cohort A and B: Disease-specific progression free survival after treatment with TARA-002

    Time frame: 60 months

  8. Cohort A and B: Overall survival after treatment with TARA-002

    Time frame: 60 months

  9. Cohort A and B: Disease specific survival after treatment with TARA-002

    Time frame: 60 months

  10. Cohort A and B: Time to cystectomy after treatment with TARA-002

    Time frame: 60 months

  11. Cohort A and B: Time to recurrence delayed cystectomy after treatment with TARA-002

    Time frame: 60 months

  12. Cohort A and B: Time to progression after treatment with TARA-002

    Time frame: 60 months

  13. Cohort A and B: Time to disease worsening after treatment with TARA-002

    Time frame: 60 months

  14. Cohort A and B: Incidence and severity of AEs, TEAEs, SAEs and TESAEs after treatment with TARA-002

    AE = adverse event; TEAE = treatment emergent adverse event; SAE = serious adverse event; TESAE = treatment emergent serious adverse event

    Time frame: Day 1 to Month 60

  15. Cohort A and B: Change from baseline in urine pharmacodynamic biomarker levels (including IL-6, IL-8, IFN-γ, and TNF-α) after treatment with TARA-002

    Time frame: Day 1 to Day 72

  16. Cohort A and B: Quality of Life based on the EORTC questionnaire QLQ-NMIBC24

    EORTC = European Organization for Research and Treatment of Cancer; QLQ-NMIBC24 = Questionnaire for Patients with NMIBC

    Time frame: Day 1 to Month 24

  17. Cohort A and B: Quality of Life based on the EORTC questionnaire QLQ-C30

    EORTC = European Organization for Research and Treatment of Cancer; QLQ-C30 = Questionnaire for Patients with Cancer

    Time frame: Day 1 to Month 24

07

Study locations

67 of 78 sites recruiting
  • Urology Centers of Alabama
    Homewood, Alabama 35209, United States
    Recruiting
    • Use Central Contact · Contact
  • Mayo Clinic
    Phoenix, Arizona 85054, United States
    Recruiting
    • Use Central Contact · Contact
  • East Valley Urology Center of Arizona
    Queen Creek, Arizona 85140, United States
    Recruiting
    • Use Central Contact · Contact
  • Arkansas Urology
    Little Rock, Arkansas 72211, United States
    Recruiting
    • Use Central Contact · Contact
  • Michael Oefelein Clinical Trials
    Bakersfield, California 93301, United States
    Recruiting
    • Use Central Contact · Contact
  • Urology Group of Southern California
    Los Angeles, California 90017, United States
    Terminated

    Not enrolling at this site — choose another above.

  • University of California Irvine Medical Center
    Orange, California 92697, United States
    Recruiting
    • Use Central Contact · Contact
  • Genesis Research
    San Diego, California 92123, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Genesis Research LLC
    Torrance, California 90505, United States
    Recruiting
    • Use Central Contact · Contact
  • Colorado University - Anshutz
    Aurora, Colorado 80045, United States
    Recruiting
    • Use Central Contact · Contact
  • AdventHealth Medical Group Urology of Denver
    Denver, Colorado 80211, United States
    Recruiting
    • Use Central Contact · Contact
  • Advanced Urology
    Lakewood, Colorado 80228, United States
    Recruiting
    • Use Central Contact · Contact
  • Urology Associates of Denver
    Lone Tree, Colorado 80124, United States
    Recruiting
    • Use Central Contact · Contact
  • University of Florida Health Jacksonville
    Gainesville, Florida 32611, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Mayo Clinic
    Jacksonville, Florida 32224, United States
    Recruiting
    • Use Central Contact · Contact
  • Comprehensive Urologic Care
    Lake Barrington, Illinois 60010, United States
    Recruiting
    • Use Central Contact · Contact
  • Southern Urology
    Lafayette, Louisiana 70508, United States
    Recruiting
    • Use Central Contact · Contact
  • Ochsner Health LSU - Regional Urology
    Shreveport, Louisiana 71105, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
    Recruiting
    • Use Central Contact · Contact
  • Greater Boston Urology, LLC
    Plymouth, Massachusetts 02360, United States
    Recruiting
    • Use Central Contact · Contact
  • Minnesota Urology, Woodbury
    Bloomington, Minnesota 55425, United States
    Recruiting
    • Use Central Contact · Contact
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
    Recruiting
    • Use Central Contact · Contact
  • Renown Regional Medical Center
    St Louis, Missouri 63110, United States
    Recruiting
    • Use Central Contact · Contact
  • Specialty Clinic Research of St. Louis
    St Louis, Missouri 63141, United States
    Recruiting
    • Use Central Contact · Contact
  • AccuMed Research Associates
    Garden City, New York 11530, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Laura & Isaac Perlmutter Cancer Center - NYU Langone Health
    New York, New York 10016, United States
    Recruiting
    • Use Central Contact · Contact
  • University of Rochester, Department of Urology
    Rochester, New York 14642, United States
    Recruiting
    • Use Central Contact · Contact
  • Associated Medical Professionals of NY, PLLC
    Syracuse, New York 13210, United States
    Recruiting
    • Use Central Contact · Contact
  • Montefiore Medical Center
    The Bronx, New York 10467, United States
    Recruiting
    • Use Central Contact · Contact
  • Cleveland Clinic Main Campus, Cleveland
    Cleveland, Ohio 44195, United States
    Recruiting
    • Use Central Contact · Contact
  • University of Toledo
    Toledo, Ohio 43606, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
    Recruiting
    • Use Central Contact · Contact
  • Carolina Urologic Research Center
    Myrtle Beach, South Carolina 29572, United States
    Recruiting
    • Use Central Contact · Contact
  • Conrad Person Clinic
    Memphis, Tennessee 38128, United States
    Recruiting
    • Use Central Contact · Contact
  • Urology Associates PC
    Nashville, Tennessee 37209, United States
    Recruiting
    • Use Central Contact · Contact
  • Amarillo Urology Research
    Amarillo, Texas 79106, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Urology Partners of North Texas
    Arlington, Texas 76017, United States
    Recruiting
    • Use Central Contact · Contact
  • Urology Austin, LLC
    Austin, Texas 78745, United States
    Recruiting
    • Use Central Contact · Contact
  • Houston Metro Urology
    Houston, Texas 77027, United States
    Recruiting
    • Use Central Contact · Contact
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
    Recruiting
    • Use Central Contact · Contact
  • Clinical Trial Network
    Houston, Texas 77074, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • UT Health San Antonio
    San Antonio, Texas 78229, United States
    Recruiting
    • Use Central Contact · Contact
  • Virginia Urology
    Richmond, Virginia 23235, United States
    Recruiting
    • Use Central Contact · Contact
  • Spokane Urology
    Spokane, Washington 99202, United States
    Recruiting
    • Use Central Contact · Contact
  • Hospital Italiano de Buenos Aires (HIBA)
    Buenos Aires, C1199ABB, Argentina
    Recruiting
    • Use Central Contact · Contact
  • Hospital Britanico de Buenos Aires
    Buenos Aires, C1280, Argentina
    Recruiting
    • Use Central Contact · Contact
  • Centro Argentino de Urologia
    CABA, C1419, Argentina
    Recruiting
    • Use Central Contact · Contact
  • Hospital Sirio Libanes
    CABA, C1419, Argentina
    Recruiting
    • Use Central Contact · Contact
  • Centro Urologico Profesor Bengio SA
    Córdoba, X5000KPH, Argentina
    Recruiting
    • Use Central Contact · Contact
  • CEMAIC
    Córdoba, X5088, Argentina
    Recruiting
    • Use Central Contact · Contact
  • Clinica Privada Independencia
    Munro, 1605, Argentina
    Recruiting
    • Use Central Contact · Contact
  • Kyushu University Hospital
    Nova Lima, Minas Gerais 34006-059, Brazil
    Recruiting
    • Use Central Contact · Contact
  • Office of Lucas Nougeria MA
    Nova Lima, Minas Gerais 34006-059, Brazil
    Recruiting
    • Use Central Contact · Contact
  • Santa Casa de Misericordia de Porto Alegre
    Porto Alegre, Rio Grande do Sul 90035-070, Brazil
    Recruiting
    • Use Central Contact · Contact
  • Nucleo de Pesquisa Clinica do Rio Grande so Sul
    Porto Alegre, Rio Grande do Sul 90430-001, Brazil
    Recruiting
    • Use Central Contact · Contact
  • Centro de Urologia Avancada
    Porto Alegre, Rio Grande do Sul 91350-200, Brazil
    Recruiting
    • Use Central Contact · Contact
  • Hospital de Clinicas da UNICAMP
    Campinas, São Paulo 13083-970, Brazil
    Recruiting
    • Use Central Contact · Contact
  • Instituto Dor de Pesquisa e Ensino
    Jardim Paulista, São Paulo 01401-002, Brazil
    Recruiting
    • Use Central Contact · Contact
  • Faculdade de Medicina ABC-CEPHO
    Santo André, São Paulo 09060-650, Brazil
    Recruiting
    • Use Central Contact · Contact
  • Exdeo Clinical Research Inc
    Abbotsford British Columbia, British Columbia V2T 1X8, Canada
    Terminated

    Not enrolling at this site — choose another above.

  • Jonathan Giddes Medicine Professional Corporation
    Brampton, Ontario L6T 4S5, Canada
    Withdrawn

    Not enrolling at this site — choose another above.

  • Sunnybrook Research Institute
    Toronto, Ontario M4N 3M5, Canada
    Withdrawn

    Not enrolling at this site — choose another above.

  • UHN Princess Margaret Cancer Centre Princess Margaret Hospital
    Toronto, Ontario M5G 1Z5, Canada
    Recruiting
  • The Research Institute of the McGill University Health Centre
    Montreal, Quebec H3H 2R9, Canada
    Recruiting
    • Use Central Contact · Contact
  • Komaki City Hospital
    Komaki-shi, Aichi-ken 485-0044, Japan
    Recruiting
    • Use Central Contact · Contact
  • Japanese Red Cross Aichi Medical Center Nayoya Daiichi
    Nagoya, Aichi-ken 435-8511, Japan
    Recruiting
    • Use Central Contact · Contact
  • Funabashi Municipal Medical Center
    Funabashi-shi, Chiba 273-8588, Japan
    Recruiting
    • Use Central Contact · Contact
  • Fuji City General Hospital
    Sakura-shi, Chiba 285-8741, Japan
    Recruiting
    • Use Central Contact · Contact
  • Kyushu University Hospital
    Fukuoka, Fukuoka 812-8582, Japan
    Recruiting
    • Use Central Contact · Contact
  • Hyogo Prefectural Amagasaki General Medical Center
    Amagasaki-shi, Hyōgo 660-8550, Japan
    Recruiting
    • Use Central Contact · Contact
  • Hitachi General Hospital
    Hitachi-shi, Ibaraki 317-0077, Japan
    Recruiting
    • Use Central Contact · Contact
  • Yokohama Municipal Citizen's Hospital
    Yokohama, Kanagawa 221-0855, Japan
    Recruiting
    • Use Central Contact · Contact
  • Niigata Cancer Center Hospital
    Niigata, Niigata 961-8566, Japan
    Recruiting
    • Use Central Contact · Contact
  • Japanese Red Cross Osaka Hospital
    Osaka, Osaka 543-855, Japan
    Recruiting
    • Use Central Contact · Contact
  • Toho University Medical Center Sakura Hospital
    Fuji-shi, Shizuoka 417-8567, Japan
    Recruiting
    • Use Central Contact · Contact
  • Toyama University Hospital
    Toyama, Toyama 930-0152, Japan
    Recruiting
    • Use Central Contact · Contact
  • Kaohsiung Medical University Chung-Ho Memorial Hospital
    Kaohsiung City, Kanagawa 807561, Taiwan
    Recruiting
    • Use Central Contact · Contact
  • Arensia Kapitanivka - PPDS
    Kapitanivka, 08111, Ukraine
    Recruiting
    • Use Central Contact · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2023 (actual). Primary completion is estimated for Oct 2031, 97 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2023
First posted
Jul 18, 2023
StartActual
Sep 15, 2023
Primary completionEst.
Oct 2031
CompletionEst.
Mar 2032
Last update
Aug 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05951179
Lead sponsor
Protara Therapeutics
Responsible party
Sponsor
First posted
Jul 18, 2023
Start date
Sep 15, 2023
Primary completion
Oct 2031 (estimated)
Completion
Mar 2032 (estimated)
Last update
Aug 24, 2026

Study contacts

Chief Scientific Operations Officer
Contact
clinicaltrials@protaratx.com
16468440337
Chief Scientific Operations Officer
study director · Protara Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Picibanil · Lyophilized Inactivated Group A Streptococcus TARA-002

Start the discussion